William M. Grady
M.D., University of Michigan - Ann Arbor, 1990.
B.S., University of Michigan - Ann Arbor, Biomedical Sciences, 1987.
Molecular and cell biology of gastrointestinal cancer: genetic and epigenetic alterations in cancer
Clinical management of gastrointestinal cancer family syndromes
Colon cancer prevention
Biomarkers for colon cancer prevention
Biomarkers for optimizing management of Barretts esophagus
(Reading, Writing, Speaking)
English: (Fluent, Fluent, Fluent)
American Association for Cancer Research
American Association for the Study of Liver Disease
American College of Gastroenterology
American Gastroenterological Association
Honors and Awards
2009, Member, Society of Clinical Investigation
2008-2013, Burroughs Wellcome Clinical Scientist Award in Translational Research, Burroughs Wellcome Fund, Fred Hutchinson Cancer Research Center
2005-2010, Presidential Early Career Award for Scientists and Engineers (PECASE), Department of Veterans Affairs
2002-2005, Mallinckrodt Scholar Award, 42nd Scholar, Edward Mallinckrodt Jr. Foundation
2002-2007, Damon Runyon-Lilly Clinical Investigator Award, Damon Runyon Cancer Research Foundation
2001, John Walsh Memorial GIDH Award in Basic Research, John Walsh Memorial
1997, ADHF Advanced Research Training Award, ADHF
1993, Outstanding Senior Resident Award, University of Michigan
American Society of Clinical Investigation Member, American Society of Clinical Investigation
2000-2004, Assistant Professor, Vanderbilt University, Gastroenterology
1999-1999, Assistant Professor, Case Western Reserve University, Gastroenterology
1998-1999, Instructor, Case Western Reserve University, Gastroenterology
1993-1994, Postdoctoral fellow, Fred Hutchinson Cancer Research Center, Laboratory of D. Hockenbery, M.D., Molecular Biology
Methods and compositions for detecting cancers associated with methylation of hMLH1 promoter DNA, Patent Number: 6858388 B2, 2005, Institution, United States.
Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2015.
Actionable exomic incidental findings in 6503 participants: challenges of variant classification.. Genome research. 25(3):305-15.. 2015.
The molecular pathogenesis of colorectal cancer and its potential application to colorectal cancer screening.. Digestive diseases and sciences. 60(3):762-72.. 2015.
Molecular markers predictive of chemotherapy response in colorectal cancer.. Current gastroenterology reports. 17(2):431.. 2015.
Patterns of DNA methylation in the normal colon vary by anatomical location, gender, and age.. Epigenetics : official journal of the DNA Methylation Society. 9(4). 2014.
Field cancerization in the colon: a role for aberrant DNA methylation? Gastroenterology report. 2(1):16-20.. 2014.
Molecular Alterations and Biomarkers in Colorectal Cancer.. Toxicologic pathology.. 2013.
Genomic Aberrations Occurring in Subsets of Serrated Colorectal Lesions but not Conventional Adenomas.. Cancer research. 73(9):2863-72.. 2013.
Survival after inflammatory bowel disease-associated colorectal cancer in the Colon Cancer Family Registry.. World journal of gastroenterology : WJG. 19(21):3241-8.. 2013.
NTRK3 is a potential tumor suppressor gene commonly inactivated by epigenetic mechanisms in colorectal cancer.. PLoS genetics. 9(7):e1003552.. 2013.
Context is everything for dependence receptors in colorectal cancer.. Proceedings of the National Academy of Sciences of the United States of America. 110(8):2697-8.. 2013.
Altered RECQ Helicase Expression in Sporadic Primary Colorectal Cancers.. Translational oncology. 6(4):458-69.. 2013.
GRG Update: DDW 2013.. Digestive diseases and sciences. 58(8):2127-8.. 2013.
A physical sciences network characterization of non-tumorigenic and metastatic cells.. Scientific reports. 3:1449.. 2013.
Therapeutic targeting of the phosphatidylinositol 3-kinase signaling pathway: novel targeted therapies and advances in the treatment of colorectal cancer.. Therapeutic advances in gastroenterology. 5(5):319-37.. 2012.
Epigenetic biomarkers in esophageal cancer.. Cancer letters.. 2012.
Fbw7 and p53 Cooperatively Suppress Advanced and Chromosomally Unstable Intestinal Cancer.. Molecular and cellular biology. 32(11):2160-7.. 2012.
TGF-β signaling promotes hepatocarcinogenesis induced by p53 loss.. Hepatology (Baltimore, Md.). 55(1):121-131.. 2012.
Variation in Age at Cancer Diagnosis in Familial versus Nonfamilial Barrett's Esophagus.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 21(2):376-383.. 2012.